Forecast

There is no analyst data available for this company.

News Go to news feed

Scancell raises £13.0m in oversubscribed placing

Scancell placed 144,444,444 shares to raise £13.0m after the originally targeted c.£9.0m was increased due to strong oversubscription. The new shares represent about 13.9% of existing ordinary shares; allocations were scaled back. Panmure Liberum acted as sole placing agent and WG Partners as joint broker. The proceeds are intended to strengthen the balance sheet and extend the company’s liquidity runway into Q3 2027; a retail offer through Winterflood additionally targets up to £2.3m. » More on de.investing.com
Scancell launches private placing of up to £2.3m

Scancell is offering private investors retail access via Winterflood for up to £2.3m and plans to issue up to around 25m new ordinary shares at 9p each, a discount of about 29.4% to the mid closing price. The offer runs until Thursday at 16:30, with a minimum subscription of £250; results are expected on Sunday morning. A separate placing to raise about $12m is running in parallel; both measures are intended to extend the company’s financial runway into the second quarter of 2027. The issue is conditional on the successful completion of the placing, and the new shares are expected to trade on AIM from Monday and will rank pari passu with existing ordinary shares. » More on de.investing.com
Scancell holds annual general meeting on 30 October in London

Scancell invites shareholders to its annual general meeting on 30 October 2025 at 3:00 p.m. GMT in London and will afterwards present the final results for the financial year ending 30 April 2025 and be available to answer questions. The annual report and financial statements will be sent to shareholders and are already available on the company website. The clinical biotech company highlights its portfolio including iSCIB1+ (phase 2), Modi-1 (phase 2) and subsidiary GlyMab Therapeutics, whose antibody projects have been partly out‑licensed to Genmab. » More on de.investing.com

Financials

In the last quarter, Scancell had revenue of 0.00€ and net profit of −6.51m€

(EUR)	Oct 2025	YoY
Revenue	0.00	-
Gross profit	−427.55k	-
Net profit	−6.51m	-
EBITDA	−6.19m	-

Fundamentals

Metric	Value
Market capitalization	+117.42m€
Number of shares	1.04b
52-week high/low	+0,34€ - +0,0916€
Dividends	No
Beta	0,69
P/E ratio	−18,30
PEG ratio	−0,19
P/B ratio	−12,02
P/S ratio	+21,37

Company profile

Scancell Holdings plc, ein biopharmazeutisches Unternehmen in der klinischen Phase, beschäftigt sich mit der Entdeckung und Entwicklung neuartiger Impfstoffe und Antikörpermedikamente zur Behandlung ungedeckter Bedürfnisse bei Krebs und Infektionskrankheiten. Zu den Produktkandidaten des Unternehmens gehören SCIB1, das sich in der klinischen Phase II zur Behandlung des metastasierten Melanoms befindet, SCIB2 zur Behandlung von nicht-kleinzelligem Lungenkrebs und Modi-1, das sich in der klinischen Phase I/II zur Behandlung von Kopf- und Halskrebs, dreifach negativem Brustkrebs, Eierstockkrebs und Nierenkrebs befindet. Das Unternehmen entwickelt auch Modi-2, das auf homocitrullinierte Krebsantigene abzielt. Darüber hinaus entwickelt das Unternehmen SCOV1 und SCOV2 COVIDITY, einen prophylaktischen DNA-Impfstoff gegen das SARS-CoV-2-Virus. Scancell Holdings plc wurde 1997 gegründet und hat seinen Sitz in Oxford, Vereinigtes Königreich.